Review
doi: 10.1053/sonc.2002.30748.
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer
Affiliations
- PMID: 11894006
- DOI: 10.1053/sonc.2002.30748
Item in Clipboard
Review
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer
Semin Oncol.
2002 Feb.
Abstract
Pemetrexed (Alimta, LY231514) is a novel, multitargeted antifolate that is broadly active in a wide variety of solid tumors, including genitourinary malignancies. This agent has also shown clinically relevant activity in combination with other agents, including gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN). Further investigation is warranted in advanced disease and adjuvant settings.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
-
Gemcitabine and Pemetrexed disodium in treating breast cancer.Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. Oncology (Williston Park). 2001. PMID: 11252887 Review.
-
Gemcitabine-based combination treatment of pancreatic cancer.Semin Oncol. 2002 Feb;29(1 Suppl 3):25-35. doi: 10.1053/sonc.2002.30749. Semin Oncol. 2002. PMID: 11894005 Review.
-
The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.Semin Oncol. 2003 Aug;30(4 Suppl 10):37-44. doi: 10.1016/s0093-7754(03)00284-7. Semin Oncol. 2003. PMID: 12947960 Review.
-
Overview of phase I/II pemetrexed studies.Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25. Oncology (Williston Park). 2004. PMID: 15655932 Review.
-
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16. doi: 10.1053/sonc.2002.37372. Semin Oncol. 2002. PMID: 12577228 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
